Innoviva to Participate in the UBS Global Healthcare Conference
13 11월 2024 - 6:05AM
Business Wire
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a
diversified holding company with a core royalties portfolio, a
leading critical care and infectious disease platform known as
Innoviva Specialty Therapeutics (“IST”), and a portfolio of
strategic investments in healthcare assets, today announced that
management will participate in a fireside chat at the UBS Global
Healthcare Conference in Ranch Palos Verdes, CA on Wednesday,
November 13, 2024 at 10:15 a.m. Pacific Time.
A live webcast of the fireside chat can be accessed under
“Events & Presentations” in the Investor Relations section of
the Company’s website at
https://investor.inva.com/presentations-events. The webcast will be
available for replay for 90 days following the event.
About Innoviva
Innoviva is a diversified holding company with a core royalties
portfolio, a leading critical care and infectious disease platform
known as Innoviva Specialty Therapeutics (“IST”), and a portfolio
of strategic investments in healthcare assets. Innoviva’s royalty
portfolio includes respiratory assets partnered with Glaxo Group
Limited (“GSK”). Innoviva is entitled to receive royalties from GSK
on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s
other innovative healthcare assets include infectious disease and
critical care assets stemming from acquisitions of Entasis
Therapeutics, including XACDURO® (sulbactam for injection;
durlobactam for injection), co-packaged for intravenous use
approved for the treatment of adults with hospital-acquired
bacterial pneumonia and ventilator-associated bacterial pneumonia
caused by susceptible strains of Acinetobacter
baumannii-calcoaceticus complex and the investigational
zoliflodacin currently being developed for the treatment of
uncomplicated gonorrhea, and La Jolla Pharmaceutical Company,
including GIAPREZA® (angiotensin II), approved to increase blood
pressure in adults with septic or other distributive shock and
XERAVA® (eravacycline) for the treatment of complicated
intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of
companies.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241112829799/en/
Innoviva, Inc. David Patti Corporate Communications (908)
421-5971 david.patti@inva.com
Investors and Media: Argot Partners (212) 600-1902
innoviva@argotpartners.com
Innoviva (NASDAQ:INVA)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Innoviva (NASDAQ:INVA)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
